Compounds > 3-deoxy-2-octulosonic acid(2)-lipid iv(a)
Page last updated: 2024-11-10
3-deoxy-2-octulosonic acid(2)-lipid iv(a)
Description
3-deoxy-2-octulosonic acid(2)-lipid IV(A): structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
(KDO)2-lipid IVA : Lipid IVA glycosylated with two 3-deoxy-D-manno-octulosonic acid (KDO) residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (13)
| Synonym |
|---|
| 143600-83-3 |
| 3-deoxy-2-octulosonic acid(2)-lipid iv(a) |
| 3-deoxy-d-manno-2-octulosonic acid(2)-lipid iva |
| kdo(2)-lipid iv(a) |
| kdo2-lipid iv(a) |
| C06025 |
| di[3-deoxy-d-manno-octulosonyl]-lipid iv(a) |
| (kdo)2-lipid iva |
| 3-deoxy-alpha-d-manno-oct-2-ulopyranonosyl-(2->4)-3-deoxy-alpha-d-manno-oct-2-ulopyranonosyl-(2->6)-2-deoxy-3-o-[(3r)-3-hydroxytetradecanoyl]-2-[(3r)-3-hydroxytetradecanamido]-4-o-phosphono-beta-d-glucopyranosyl-(1->6)-2-deoxy-3-o-[(3r)-3-hydroxytetradeca |
| CHEBI:28526 |
| DTXSID20162477 |
| Q27103755 |
| (2r,4r,5r,6r)-4-[(2r,4r,5r,6r)-2-carboxy-6-[(1r)-1,2-dihydroxyethyl]-4 ,5-dihydroxy-oxan-2-yl]oxy-6- |
Roles (1)
| Role | Description |
|---|
| Escherichia coli metabolite | Any bacterial metabolite produced during a metabolic reaction in Escherichia coli. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
| Class | Description |
|---|
| lipid As | Glycophospholipids that are the components of endotoxins held responsible for the toxicity of Gram-negative bacteria. Lipid A is the innermost of the three regions of the lipopolysaccharide (LPS) molecule, and its hydrophobic nature allows it to anchor the LPS to the outer membrane. Four acyl chains attached directly to two (1->6)-linked glucosamine sugars are beta-hydroxy acyl chains usually between 10 and 16 carbons in length. Two additional acyl chains are often attached to the beta-hydroxy group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (77.78) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.05
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.05 (24.57) | | Research Supply Index | 2.30 (2.92) | | Research Growth Index | 4.35 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |